Several clinical trials have evaluated naltrexone as a treatment for alcohol use disorders (AUDs), but few have focused on women. The aim of this review was to systematically review and summarize the evidence regarding the impact of naltrexone compared to placebo for attenuating alcohol consumption in women with an AUD. A systematic review was conducted using PubMed, Cochrane, Web of Science, CINAHL, and Alcohol Studies Database to identify relevant peer-reviewed randomized controlled trials (RCTs) published between January 1990 and August 2016. Seven published trials have evaluated the impact of naltrexone on drinking outcomes in women distinct from men; 903 alcohol-dependent or heavy drinking women were randomized to receive once daily oral or depot (injectable) naltrexone or placebo with/without behavioral intervention. Two studies examining the quantity of drinks per day observed trends toward reduction in drinking quantity among women who received naltrexone versus placebo. The 4 studies examining the frequency of drinking had mixed results, with 1 study showing a trend that favored naltrexone, 2 showing a trend that favored placebo, and 1 that showed no difference. Two of the 3 studies examining time to relapse observed trends that tended to favor naltrexone for time to any drinking and time to heavy drinking among women who received naltrexone versus placebo. While the growing body of evidence suggests a variety of approaches to treat AUD, the impact of naltrexone to combat AUD in women is understudied. Taken together, the results suggest that naltrexone may lead to modest reductions in quantity of drinking and time to relapse, but not on the frequency of drinking in women. Future research should incorporate sophisticated study designs that examine gender differences and treatment effectiveness among those diagnosed with an AUD and present data separately for men and women.
I
N THE UNITED States, alcoholism is a prevalent and costly public health issue with women representing the fastest-growing population of alcohol users (Krystal et al., 2001 ; National Council on Alcoholism and Drug Dependency, Inc., 2015) . The National Institute on Alcohol Abuse and Alcoholism (NIAAA) (2016a,b) estimates that 5.7 million women over 18 years in the United States have an alcohol use disorder (AUD); the term used to describe problem drinking and is classified as mild, moderate, or severe (NIAAA 2016a,b; SAMHSA, 2012) . Consequently, AUDs are the fourth leading preventable cause of death in the United States (Mokdad et al., 2004; Stahre et al., 2014) .
Multiple psychosocial, behavioral, and pharmacotherapy interventions have been shown to be effective in treating an AUD; however, the relapse rate approximates 70% (Moos and Moos, 2006) . The primary treatment goals for an AUD are abstinence from drinking or reduction in heavy drinking (Jonas et al., 2014; Maisel et al., 2013; Srisurapanont and Jarusuraisin, 2005) . Thus, women present a special subset of an AUD as a result of physiologic status, psychosocial factors, and genetic considerations (Diehl et al., 2007; Greenfield et al., 2010; Mann et al., 1992 Mann et al., , 2005 Ponce et al., 2004) . Women who consume an extreme amount of alcohol can subject themselves to immediate effects that can increase their risk of harmful health conditions (CDC, 2016c) . Likewise, excessive alcohol consumption can lead to the development of chronic diseases and other serious problems such as developing alcohol dependence or alcoholism (CDC, 2016a,b) . While several medications (i.e., naltrexone, acamprosate, disulfiram) have been used to reduce heavy drinking and increase days of alcohol abstinence in drinkers, the efficacy of these interventions varies considerably (Carmen et al., 2004; Jonas et al., 2014; Maisel et al., 2013; Srisurapanont and Jarusuraisin, 2005; Streeton and Whelan, 2001) .
As previously mentioned, naltrexone is a prescription medication that has been approved by the U.S. Food and Drug Administration and promoted for use in AUD populations (Garbutt et al., 2005; Hernandez-Avila et al., 2006; Roozen et al., 2007) . Naltrexone acts to decrease alcohol cravings and reduce the reinforcing effects of alcohol consumption by blocking opioid-mediated increases in central dopamine release (Gianoulakis, 2001) . Administration options include oral medication once per day or a once-amonth injectable (Garbutt et al., 2005; Hernandez-Avila et al., 2006; Roozen et al., 2007) . While the optimal dose of naltrexone is not known, most studies used 50 mg/d (range 50 to 150 mg). Moreover, studies have reported that naltrexone is more effective than other pharmacotherapies particularly when combined with behavioral treatment (Anton et al., 2006; O'Malley et al., 2007) . However, clinical trials evaluating combinations of naltrexone and behavioral interventions have demonstrated mixed results (Anton et al., 2006; Garbutt et al., 2014; Lovallo et al., 2012; Ponce et al., 2004) . Most importantly, gender differences (i.e., absorption, genetics, vulnerability) underscore the need to evaluate the impact of specific treatment options for AUDs in women. While recent systematic reviews suggest slight benefit from naltrexone (Donoghue et al., 2015; Jonas et al., 2014; Kranzler et al., 2009 ), they do not specifically address variables specific to naltrexone treatment in women. Against this background, the objective of this article was to systematically review and summarize the evidence regarding the impact of naltrexone versus placebo for attenuating alcohol consumption in women with an AUD.
MATERIALS AND METHODS

Search Strategy
From January 1990 to August 2016, we queried online databases PubMed, Cochrane, Web of Science, CINAHL, and the Alcohol Studies Database for peer-reviewed original human research (Fig. 1) . A search was undertaken using the following search terms: naltrexone AND (alcohol; OR alcohol dependence; alcohol use disorders; hazardous drinking; heavy drinking; binge drinking; alcohol consumption) AND (women; OR female). Additional searches of Google Scholar and references of identified secondary literature were also carried out. This review included all relevant randomized controlled trials (RCTs). The first author (SSC) screened all eligible articles for relevance using titles and abstracts. Additionally, 3 researchers (GDC, CLC, and RLC) independently reviewed eligible papers.
This review included trials that evaluated the impact of naltrexone on drinking outcomes in women alone or distinct from men. This review used the following inclusion/exclusion criteria: (i) must include a RCT design, (ii) published in English or capable of being translated, (iii), published between 1990 and 2016, (iv) intervention was oral or injectable naltrexone with or without behavioral intervention, (v) assessed a measurable drinking outcome, (vi) study must present results for women alone or distinct from men, and (vii) participants were 18 years of age or older. For the purposes of this review, we included only clinical trials as defined by the National Cancer Institute (Cancer.gov, 2015) as, "a study in which participants are randomly assigned (by chance) to receive one of the several pharmacotherapies and/or behavioral interventions."
For each eligible study, we abstracted information on the study population, intervention and comparison group, and main results. Because each study had different measures of alcohol use and slightly different combinations of treatments, we did not create a summary measure of risk; rather, we provided the results of each study. Drinking outcomes reported in the studies could be grouped into 3 general categories, including alcohol quantity (drinks per day, reduction in drinks/d, drinks per drinking day), frequency of drinking (d/month, percent drinking days [%] , percent heavy drinking days [%] , percent days abstinent [%]), and/or to time to relapse (time to any drinking, time to heavy drinking). Results were presented as significant differences if there was a statistically significant result (p < 0.05); as trends if there was at least a 20% difference in outcomes, but the p-value was either not significant or not reported; and as "no difference" if the results were essentially the same or p-value was >0.5.
RESULTS
The screening of relevant titles yielded a total of 2,765 articles. After reviewing the full-text articles (n = 37), an additional 30 studies were eliminated. The 7 studies included in this review presented drinking outcomes for women distinct from men. Five studies were double-blind RCTs, one study was a factorial design RCT, and another study conducted an exploratory analysis post hoc analysis from a double-blind RCT. Participants were randomized to a group treated with naltrexone (either oral once daily or targeted (drinking days only) 50 to 150 mg or injectable naltrexone 380 or 190 mg, with or without a behavioral intervention or to a group receiving placebo with or without a behavioral intervention.
Six studies enrolled participants with alcohol dependence, diagnosed by the American Psychiatric Association's Diagnostic and Statistical Manual, Fourth Edition (DSM-IV) (Garbutt et al., 2005; Greenfield et al., 2010; Kiefer et al., 2005; Kranzler et al., 2009; O'Malley et al., 2007; Pettinati et al., 2008) . All of the studies except Pettinati and colleagues (2008) excluded persons who were dependent on substances other than alcohol or nicotine. The 7 studies included a total of 2,590 randomized participants, of whom 903 were women with a mean age range 39.2 to 49. In the 4 studies that reported race/ethnicity, the majority of women were Caucasian (n = 576), followed by Hispanic (n = 38), and then African American (n = 37). Five studies reported the proportion of women who received naltrexone (daily or targeted) (n = 271) or placebo (n = 202) (Garbutt et al., 2005; Greenfield et al., 2010; Kiefer et al., 2005; O'Malley et al., 2007; Pettinati et al., 2008) . All of the studies reported the timing of intervention application, ranging from 8 to 16 weeks. Furthermore, the 7 studies utilized variable participant recruitment methods: advertisements (Greenfield et al., 2010; Hernandez-Avila et al., 2006; O'Malley et al., 2007) , clinicians referrals (Hernandez-Avila et al., 2006; Kranzler et al., 2009) , alcohol treatment study sites (Greenfield et al., 2010; Kiefer et al., 2005; O'Malley et al., 2007; Pettinati et al., 2008) , public hospitals, private and Veteran Administration clinics, or tertiary care settings (Garbutt et al., 2005) .
Study Summaries
Detailed information about each study is as follows (Table 1 includes study summary). Kranzler and colleagues (2009) conducted a 12-week factorial design study in the United States to determine the impact of targeted use of naltrexone to reduce heavy drinking. A total of 163 alcoholdependent randomized participants (95 men and 68 women) received daily or targeted naltrexone (50 mg/d) or daily or targeted placebo. The authors measured the drinking outcome drinks per day at multiple time points. Greenfield and colleagues (2010) conducted a secondary analysis of the COMBINE Study (a national, multisite 16-week double-blind study in the United States) to assess gender differences in treatment outcomes. A total of 1,226 alcohol-dependent randomized participants (848 men and 378 women) assigned to 1 of 8 groups received medical management with active naltrexone (100 mg/d) or placebo, active acamprosate (3 g/d) or placebo, with or without a cognitive behavioral intervention. The study assessed drinking outcomes percent days abstinent, percent heavy drinking days, and time to first heavy drinking day.
O'Malley and colleagues (2007) conducted a double-blind, 12-week study in the United States to investigate the safety and efficacy of oral naltrexone 50 mg in a sample of 103 alcohol-dependent randomized women who received naltrexone or placebo. The study assessed drinking outcomes percent days abstinent, percent heavy drinking days, and time to first heavy drinking day. Garbutt and colleagues (2005) conducted a 24-week double-blind study in the United States to determine the efficacy and tolerability of a long-acting intramuscular formulation of naltrexone. A total of 624 alcohol-dependent randomized participants (423 men and 201 women) received long-acting injectable naltrexone (380 or 190 mg) or placebo and standardized supportive therapy. The study measured the drinking outcome number of heavy drinking days at multiple time points. Kiefer and colleagues (2005) conducted an exploratory analysis post hoc from Kiefer and colleagues (2003) (a 12-week double-blind study in Germany) to compare and combine naltrexone and acamprosate in relapse prevention in alcoholism. A total of 160 alcohol-dependent randomized participants (118 men and 42 women) assigned to 1 of 4 groups received active naltrexone (50 mg/d), acamprosate (1,998 mg/d), naltrexone plus acamprosate, or placebo. The authors measured drinking outcomes mean time to first drink and mean time to relapse.
Hernandez-Avila and colleagues (2006) conducted a secondary analysis of a study by Kranzler and colleagues (2003) (an 8-week double-blind study in the United States) to examine the effects of daily naltrexone and targeted scheduled administration on a continuous outcome of drinks/d. A total of 150 heavy drinking randomized participants (87 men and 63 women) assigned to 1 of 4 Pettinati and colleagues (2008) conducted a 12-week double-blind study in the United States to determine the efficacy of a higher-than-normal daily dose of naltrexone among treatment-seeking participants with co-occurring cocaine and alcohol dependence. A total of 164 alcohol-dependent randomized participants (116 men and 48 women) received naltrexone (150 mg/d) or placebo with cognitive behavioral therapy or medical management. The study measured drinking outcomes abstinence (yes/no), number of drinks per drinking day, the percentage of drinking days, and the percentage of heavy drinking days at multiple time points.
Study Outcomes
Overall, study outcomes focused on alcohol quantity (drinks per day, reduction in drinks/d, drinks per drinking day), frequency of drinking (days/month, percent drinking days [%] , percent heavy drinking days [%] , percent days abstinent [%]), and/or time to relapse (time to any drinking, time to heavy drinking).
Three studies reported findings related to drinking quantity. Kranzler and colleagues (2009) reported no difference in women's drinking across the 4 study conditions (e.g., daily naltrexone, daily placebo, targeted naltrexone, and targeted placebo). However, a trend toward reduced alcohol consumption was observed among women at study week 12 in the daily naltrexone group compared to the daily placebo group (naltrexone group: 2.6 drinks per day vs. placebo group: 3.5 drinks per day) (no p-value reported) (Kranzler et al., 2009 ). Hernandez-Avila and colleagues (2006) reported no difference in mean drinks per day outcome among women at week 8 who received targeted naltrexone (2.75 drinks), targeted placebo group (2.5 drinks), daily naltrexone (2 drinks), or daily placebo (2 drinks) (no p-value reported). Pettinati and colleagues (2008) observed a trend toward reduced number of drinks per drinking day among women who received naltrexone (3.7 drinks [3.1]) versus placebo (6.4 drinks [6.7]) (no p-value reported).
Four studies considered the frequency of drinking as an outcome. Greenfield and colleagues (2010) observed a trend toward increased percentage of days abstinent among women who received naltrexone (78%) compared to placebo (71%) (p = 0.092), and a trend toward decreased percentage of heavy drinking days was observed among women receiving naltrexone (naltrexone 14% of days vs. placebo: 20.5% of days) (no p-value reported). O'Malley and colleagues (2007) reported no difference in percent days abstinent (p > 0.30) or percent heavy drinking days (p > 0.30) among women who received naltrexone or placebo (actual results not provided). Pettinati and colleagues (2008) Three studies reported findings on the time to first drink outcome. Kiefer and colleagues (2005) observed a significantly longer time to first drink among women who received oral naltrexone (68.9 AE 8.7 days) versus placebo (19.2 AE 6.1 days) (p < 0.001); and a significant increase in time to first heavy drinking day among women who received naltrexone (77.0 AE 8.0 days) versus placebo (32.2 AE 8.0 days) (p < 0.05). Greenfield and colleagues (2010) observed a trend in longer time to relapse to first heavy drinking day (number of days in which 50% of the sample returned to drinking) among women who received naltrexone (42 days) versus placebo (18 days) (p-value not reported). O'Malley and colleagues (2007) found no significant difference in time to return to drinking among women who received naltrexone (30 days) versus placebo (40 days) (p = 0.88).
DISCUSSION
Our review systematically reviewed and summarized the evidence regarding the impact of naltrexone compared to placebo for attenuating alcohol consumption. To date, this is the first systematic literature review that focuses solely on women with an AUD. Our review identified 7 studies conducted between 1990 and 2016 that met the a priori inclusion criteria. Two of the 3 studies examining the quantity of drinks per day observed trends toward reduction in drinking quantity among women who received naltrexone versus placebo. The 4 studies examining the frequency of drinking had mixed results, with 1 study showing a trend that favored naltrexone, 2 showing a trend that favored placebo, and 1 that showed no difference. Two of the 3 studies examining time to relapse observed trends that tended to favor naltrexone for time to any drinking and time to heavy drinking among women who received naltrexone versus placebo. Taken together, the results suggest that naltrexone may lead to modest reductions in quantity of drinking and time to relapse, but not on the frequency of drinking in women. However, among 7 studies, only 1 reported a statistically significant improvement in drinking outcomes among women who received naltrexone versus placebo.
Due to a limited amount of research examining gender difference regarding naltrexone's effectiveness coupled with the variability in intervention prescription dosage/duration, it is not possible to identify the optimal approach for use of naltrexone to treat AUDs in women. Unlike previously conducted systematic reviews (Maisel et al., 2013; Srisurapanont and Jarusuraisin, 2005) , our review focused on women with an AUD or other evidence of serious drinking. Thus, this review was imperative given that many studies have not explored gender differences in the efficacy of naltrexone for women distinct from men. Six studies reported results for both men and 3 of these observed trends that indicated the effect of naltrexone to reduce drinking was stronger in men than in women (Garbutt et al., 2005; Kranzler et al., 2009; Pettinati et al., 2008) .
We note several potential limitations as context for interpreting our findings. Four studies included fewer than 100 women and were relatively underpowered to detect significant changes in drinking over time (Hernandez-Avila et al., 2006; Kiefer et al., 2005; Kranzler et al., 2009; Pettinati et al., 2008) . Due to the low representation of minority women in the 7 studies, results may not be generalizable to women of other ethnic/racial groups. Next, the intervention components varied across all of the studies with some women receiving more counseling interventions than others. Additionally, the measurement of alcohol consumption is limited to self-report, and our review only included 1 study using depot (injectable) naltrexone (Garbutt et al., 2005) . Most notably, the review lacked studies with common intervention strategies or outcome measures to justify doing a statistical summary of effect using meta-analysis techniques as done in other reviews.
In summary, the limited existing evidence suggests that naltrexone may have a very modest effect on drinking quantity and time to relapse, but not on overall frequency of drinking among women. Over time, better interventions are needed that can demonstrate a greater magnitude of effect. While the growing body of evidence suggests a variety of pharmacotherapy and behavioral intervention approaches to treat AUD, the impact of naltrexone on combating AUD in women is understudied. Future research should incorporate sophisticated study designs that examine gender differences and treatment effectiveness among those diagnosed with an AUD and present data separately for men and women. This may lead to the development of better treatment options for women or the ability to identify the subset of women who might benefit most from naltrexone.
